埃克替尼治疗晚期非小细胞肺癌有效性与安全性的Meta分析

目的:系统评价埃克替尼治疗晚期非小细胞肺癌(NSCLC)的有效性和安全性,为临床合理用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、ScienceDirect、中国知网数据库、万方数据库和维普数据库,收集埃克替尼或埃克替尼联合常规治疗或联合其他药物治疗(试验组)对比常规治疗或其他药物(对照组)治疗晚期NSCLC的随机对照试验(RCT)。经筛选文献、提取资料并采用Cochrane协作网提供的5.1.0偏倚风险评估工具评价文献质量后,采用Rev Man 5.3软件进行Meta分析。结果:共纳入27项RCT,合计2 345例患者。Meta分析结果显示,试验组患者有效率OR=1.64,95%CI(1.36,1.97),P<0.000 01]、疾病控制率OR=1.68,95%CI(1.39,2.04),P<0.000 01]均显著高于对照组,不良反应发生率OR=0.59,95%CI(0.48,0.72),P<0.000 01]显著低于对照组。结论:埃克替尼治疗晚期NSCLC的有效性与安全性均较好。

Efficacy and Safety of Icotinib in the Treatment of Advanced Non-small Cell Lung Cancer:a Meta-analysis

OBJECTIVE:To evaluate the efficacy and safety of icotinib in the treatment of advanced non-small cell lung cancer(NSCLC),and to provide evidence-based reference for clinical drug use.METHODS:Retrieved from the Cochrane library,PubMed,Sciencedirect,CNKI,Wanfang database and VIP,RCTs about icotinib or icotinib combined with routine treatment or with other drugs(trial group)versus routine treatment or other drugs(control group)in the treatment of advanced NSCLC were collected.After literature screening,data extraction and literature quality evaluation with Cochrane collaboration bias risk assessment tool 5.1.0,Meta-analysis was performed by using Rev man 5.3 statistical software.RESULTS:A total of 27 RCTs were included,involving 2 345 patients.Results of Meta-analysis showed that response rateOR=1.64,95%CI(1.36,1.97),P<0.000 01]and disease control rateOR=1.68,95%CI(1.39,2.04),P<0.000 01]in trial group were significantly higher than control group;the incidence of ADR in trial groupOR=0.59,95%CI(0.48,0.72),P<0.000 01]was significantly lower than control group.CONCLUSIONS:Icotinib shows good efficacy and safety in the treatment of advanced NSCLC.